PureTech Sees Cash Burn Falling as Portfolio Funding Shifts
The biotech reported a first-half profit driven by investment gains and said its lower-cost model should extend its cash runway through 2028.
Makkler Newsroom · Sep 24, 12:06 AM · 2 min read
